Journals LibraryNHS NIHR - National Institute for Health Research
HTA - 09/141/01
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (Review of TA 110): systematic review and economic evaluation
Project title: Rituximab for the first-line treatment of stage III-IV follicular lymphoma (Review of TA 110): systematic review and economic evaluation
Call to action: 14/133 Batch 10
Research type: Evidence Synthesis
Chief investigator: Ms Diana Papaioannou
Lead Author: Ms Diana Papaioannou
Contractor: The University of Sheffield
Co-investigators: Professor Matt Stevenson.
Started: December 2010 | Status: Published October 2012
Study finds that the combination of rituximab with chemotherapy is likely to be clinically effective in the first-line treatment of stage III-IV follicular lymphoma. The cost per quality-adjusted life-year gained is estimated to be £25,000 for all three chemotherapy regimens compared and is considerably lower if first-line rituximab maintenance is not assumed.
Links to project documentation
The links and documents below are related to this research and are added as and when they are produced over the life of the project. The information is provided by the researchers and some may have undergone varying editorial, production and publication models, which differ to NIHR Journals Library reports. Links are to both internal (NIHR) and external websites – the NIHR is not responsible for the content of external websites.